Comparison at a glance
Semaglutide (GLP-1 receptor agonist) Chronic weight management; roughly 10–15% body-weight reduction vs placebo in obesity RCTs Strong human RCT — approved medicine (marketed as Wegovy) Prescription drug; GI s…
Approved comparison material connected to this topic.
5 total recordsSource comparisons are presented without a generated winner.
Semaglutide (GLP-1 receptor agonist) Chronic weight management; roughly 10–15% body-weight reduction vs placebo in obesity RCTs Strong human RCT — approved medicine (marketed as Wegovy) Prescription drug; GI s…
AOD-9604 Direct lipolysis signalling Adipocyte mobilisation Selective fat mobilisation Tesamorelin GHRH-mediated GH elevation Visceral fat reduction Metabolic dysfunction CJC-1295 + Ipamorelin Sustained GH ele…
Researchers searching for the best peptides for fat loss often have different goals than those searching for “weight loss peptides.” Fat loss implies body composition change — reducing adipose tissue while pot…
Retatrutide Triple GIP/GLP-1/glucagon agonist Up to 24.2% weight loss (Phase 2, 48 weeks) $39.99-$119.99 Tirzepatide Dual GIP/GLP-1 agonist Up to 20.9% weight loss (SURMOUNT-1, 72 weeks) $54.99-$104.99 AOD-960…
The table below compares the best peptides for fat loss across mechanism, clinical evidence, typical dosing, and practical limitations. Each peptide targets a different physiological pathway. Selecting the rig…